A business development and strategy executive with a career built at the intersection of science, finance, and commercial creativity. Operates across life sciences, specialty pharma, rare disease, and adjacent industries, with a track record of surfacing under-indexed opportunities, architecting complex deals, and crafting new businesses and revenue streams from the ground up, drawing on experience gained across all sides of the deal table.
At a Glance
~$2B
Led and executed in acquisitions, divestitures, and global licensing
$275M
PE exit, supported ~35% uplift
45%
Milestone uplift, Japan partnership
6+ yrs
IP runway extension
5 to 14
Annual FDA submissions increased
Areas of Expertise
Strategic in- and out-licensing
M&A, divestitures, and partnerships
Deal sourcing, structuring, and negotiation
Adjacent market expansion
New business case modeling
Cross-functional due diligence leadership
C-suite and Board presentations
Rare disease and specialty pharma
R&D portfolio strategy and optimization
Selected Achievements
Deal Architecture and Value Creation
- Sourced and advanced an under-indexed, de-risked asset mis-staged in global databases and therefore invisible to others; asset is positioned to become Standard of Care, extending company IP runway by 6+ years with near-term revenue accretion.
- Negotiated a Japan rare disease partnership, bridging divergent regulatory and commercial frameworks; uplifted milestones 45% and secured tiered double-digit royalties with tail.
- Identified and secured a de-risked Phase III asset that became the company's lead product, successfully launched four years later.
- Structured portfolio valuations and business case enabling a $10M private placement and a successful spinout.
- Presented company to Wall Street as one of three C-suite executives, securing a $6M private placement with a $2M follow-on.
Growth Strategy and New Venture Creation
- Architected an informatics company's growth strategy by designing a new service repurposing medical data for earlier rare disease diagnosis and trial referrals; helped increase valuation ahead of its $275M PE acquisition, with a projected ~35% uplift.
- Evaluated joint venture and adjacent-market opportunities for a Fortune 500 utility navigating industry deregulation, advising on entry into telecommunications and other sectors.
- Built a multi-company business from a single product line into four distinct revenue streams, adding a consulting arm and developing expertise in product positioning, niche marketing, and media relations.
- Built a pipeline of near-term, synergistic follow-on opportunities supporting sustained growth optionality.
Enterprise Value and Portfolio Optimization
- Designed a predictive valuation model that ranked and prioritized 300+ pipeline assets, improving R&D resource allocation and increasing annual FDA submissions from 5 to 14.
- Led a Fortune 500 company's transition from EPS targets to cash-based value measures across seven business units, improving shareholder value alignment by approximately 30%.
- Partnered with Boston Consulting Group to drive portfolio-wide value management strategy; mentored senior executives and trained analysts on value creation frameworks.
Experience
Paratek Pharmaceuticals, King of Prussia, PA
Vice President, Business Development
A PE-backed commercial pharmaceutical company
2024 – Present
Intercept Pharmaceuticals, Morristown, NJ
Global Head, Business Development
A publicly traded commercial biopharmaceutical company
2021 – 2024
Alyon Inc., Hackensack, NJ
Head of Business Development, North America
The US subsidiary of a Swiss pharmaceutical company
2016 – 2021
Luminant LLC, Stamford, CT
Principal, Business Development and Strategy
A life sciences business development consultancy
2008 – Present
Earlier Strategy and Finance Experience
Innapharma, Inc., Suffern, NY
Acting CFO
A pharmaceutical company with an in-house Contract Research Organization (CRO)
Taro Pharmaceuticals USA, Hawthorne, NY
Director, Financial Analysis and Strategic Planning
A publicly traded multinational pharmaceutical company
Public Service Electric and Gas (PSE&G), Newark, NJ
Business Analysis Manager
A Fortune 500 electric and gas utility company
Education
Master of Business Administration (MBA), Finance and International Business
Stern School of Business, New York University, New York, NY
Bachelor of Science (B.Sc.), Cum Laude in Chemistry
The Hebrew University, Jerusalem, Israel
Synthesized and characterized a novel compound, poly-bis(μ-diphenyl-phosphinato)copper(II); co-authored the findings in the peer-reviewed journal Inorganica Chimica Acta, cited 21 times. Received three academic achievement awards.
Honors
Management Honors Program, Weizmann Institute, Rehovot, Israel. Selected as one of the top ten graduates across all universities; awarded a scholarship for excellence
